ACADIA Pharmaceuticals Inc. (ACAD)
| Market Cap | 3.83B |
| Revenue (ttm) | 1.07B |
| Net Income (ttm) | 391.00M |
| Shares Out | 170.49M |
| EPS (ttm) | 2.30 |
| PE Ratio | 9.77 |
| Forward PE | 46.13 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 636,894 |
| Open | 22.47 |
| Previous Close | 22.30 |
| Day's Range | 22.30 - 22.68 |
| 52-Week Range | 14.18 - 28.35 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 30.55 (+35.84%) |
| Earnings Date | May 6, 2026 |
About ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting sy... [Read more]
Financial Performance
In 2025, ACADIA Pharmaceuticals's revenue was $1.07 billion, an increase of 11.87% compared to the previous year's $957.80 million. Earnings were $391.00 million, an increase of 72.66%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price target is $30.55, which is an increase of 35.84% from the latest price.
News
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of ...
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. f...
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide, is ...
ACADIA Pharmaceuticals Transcript: Stifel 2026 Virtual CNS Forum
Remlifanserin is advancing in robustly designed trials for Alzheimer's and Lewy body dementia psychosis, with a focus on improved efficacy, safety, and regulatory alignment. The phase II readout is expected between August and October, while a novel R-ketamine asset is progressing in MDD.
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:...
ACADIA Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026
Strong commercial growth and robust financials support ongoing investment in a diverse pipeline, with key catalysts including the remlifanserin phase II readout and new DAYBUE formulation. Expansion efforts target both US and international markets, despite regulatory challenges.
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on ...
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed th...
ACADIA Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Management projects $1.7B in 2028 sales, driven by NUPLAZID and DAYBUE, with new formulations and expanded field force fueling growth. Remlifanserin phase II data is expected by fall, and regulatory reexamination for DAYBUE in Europe will include patient advocacy.
ACADIA Pharmaceuticals Earnings Call Transcript: Q4 2025
Adjusted revenues grew 14% to $1.08B in 2025, with NUPLAZID and DAYBUE both posting double-digit sales growth. 2026 guidance projects continued strong momentum, supported by new product launches, expanded field teams, and a robust R&D pipeline.
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2025. “Acadia closed 2025 with ano...
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference Fi...
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after th...
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company was informed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medici...
ACADIA Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted robust commercial growth for NUPLAZID and DAYBUE, ambitious global expansion, and a diversified pipeline with multiple late-stage milestones expected by 2027. AI-driven innovation and targeted business development underpin the strategy for sustained growth.
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's neurological and rare disease drug candidates, which will...
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Ad...
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE® STIX (trofinetide) for oral solution, a dye...
ACADIA Pharmaceuticals Transcript: Citi Annual Global Healthcare Conference 2025
Strong commercial growth for NUPLAZID and DAYBUE is supported by renewed investments and expanded field force, with both products showing robust patient retention and market penetration. Key pipeline assets, including ACP-204 for ADP and LBDP, are advancing, and the company maintains a strong financial position with growing profitability.
Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Citi's 2025 Global Healthcare Conference on Tuesday, December 2, 2...
ACADIA Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025
Aiming for global leadership in neurological and rare diseases, the company projects over $1 billion in 2025 revenue, driven by NUPLAZID and DAYBUE, and expects major pipeline milestones—including ACP-204 and DAYBUE regulatory decisions—by 2026. Expansion into new therapeutic areas and global markets is underway.
ACADIA Pharmaceuticals Transcript: UBS Global Healthcare Conference 2025
Nuplazid and Daybue are on track for over $1 billion in annual revenue, with Nuplazid's sales force expanding 30% in January and Daybue seeing record referrals after its own expansion. The pipeline remains robust, led by ACP-204 in Phase II for Alzheimer's and Lewy body dementia psychosis.
ACADIA Pharmaceuticals Earnings Call Transcript: Q3 2025
Q3 2025 revenues rose 11% year-over-year to $278.6M, with DAYBUE and NUPLAZID both posting record sales and strong prescription growth. Strategic investments in salesforce expansion and R&D are expected to drive continued momentum, with updated 2025 guidance reflecting this strength.
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2025. “Acadia delivered another strong quarter, g...
Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) breached their fiduciary...